REG - Spire Healthcare Grp - Agreement in principle with NHS England

Spire HealthcareAnnouncement

10/01/2022 07:05

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220110:nRSJ8485Xa&default-theme=true

RNS Number : 8485X  Spire Healthcare Group PLC  10 January 2022

Spire Healthcare Group plc

 

("Spire Healthcare", "the Company" or "the Group")

 

Agreement in principle with NHS England to provide further COVID-19 support

 

10 January 2022

 

Spire Healthcare Group plc (LSE: SPI), a leading UK independent hospital
group, announces that, at the request of NHS England ("NHSE"), it has reached
an agreement in principle to provide support to the NHS and its patients
during the ongoing COVID-19 pandemic. This agreement follows detailed
discussions with NHSE and other independent providers, in light of the
uncertainties created by the Omicron variant.

 

While the final details of a new contract have yet to be agreed, it will
operate on similar terms to the contract in place during Jan-Mar 2021 which
was announced on 21 December 2020. The agreement in principle is for payment
by activity based on NHS tariff, with minimum value underpins.

 

Work under the agreement in principle will commence on Monday 10 January and
expire on 31 March 2022. There will be no extension or cancellation unless
mutually agreed.

 

Under the agreement, Spire Healthcare, together with other independent
providers, will continue to relieve pressure on NHS hospitals in England by
treating NHS elective patients and providing urgent cancer work. The agreement
will allow Spire Healthcare to continue to treat private patients, whilst
supporting the NHS.

 

If required, subject to meeting agreed criteria, Spire Healthcare will grant
NHSE access to 100% of its facilities and teams on a local, regional or
national basis in the event of a surge of COVID-19 patients in NHS hospitals
in England. If a Spire Healthcare hospital is in surge, Spire Healthcare will
receive 100% cost recovery for its services.

 

This announcement contains inside information for the purposes of Article 7 of
EU Regulation 596/2014.

 

- Ends -

 

For further information please contact:

 

Spire Healthcare

Angus Prentice - Interim Head of Investor Relations        +44 (0)7974
982 512

 

Instinctif Partners

Damian
Reece
+44 (0)7931 598 593

Guy
Scarborough
+44 (0)7917 178 920

Jeremy
Durrant
            +44 (0)7792 918 648

 

Registered Office and Head Office:

 

Spire Healthcare Group plc

3 Dorset Rise

London

EC4Y 8EN

Registered number 09084066

 

About Spire Healthcare

 

Spire Healthcare is a leading independent hospital group in the United
Kingdom, with 40 private hospitals and eight clinics across England, Wales and
Scotland.

 

Working in partnership with around 7,500 experienced consultants, Spire
Healthcare delivered tailored, personalised care to almost 750,000 in-patients
and daycase patients in 2020, and is the leading private provider, by volume,
of knee and hip operations in the United Kingdom.

 

The Group's well-located and scalable hospitals have delivered successful and
award-winning clinical outcomes, positioning the Group well with patients,
consultants, the NHS, GPs and Private Medical Insurance ("PMI") providers. 90%
of Spire Healthcare's hospitals are rated 'Good' or 'Outstanding' by the CQC
(or the equivalent in Scotland and Wales).

 

Spire Healthcare treats patients through a variety of routes including PMI,
Self-pay and the NHS, providing the Group with diversified access to the
expected growth opportunities in the UK healthcare market, which faces
significant supply challenges as a result of NHS budget constraints and
increasing demand from a growing population with longer life expectancy.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGREASFNEDKAEFA